MeSH tree: E02.815.814
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with low rejection rates and also may preserve fertility, according to results of a new study conducted ...
May 6, 2026
0
2
People who have elevated levels of donor-specific anti-HLA antibodies (DSAs)—immune system proteins that can target and attack donor stem cells—wait an average of three additional months to receive blood or bone marrow transplants ...
Apr 14, 2026
0
2
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning ...
Dec 8, 2025
0
6
A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins ...
Feb 25, 2025
0
51
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) can cure hematopoietic diseases, such as acute myeloid leukemia. Cord blood transplantation (CBT), which accounts for more than one-third of allo-HSCTs in Japan, ...
Jan 24, 2024
0
31
Lymph node (LN) metastasis is a sign that things are going from bad to worse in cancer patients, and prompt treatment is vital.
Sep 14, 2022
0
40
